{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:44:40Z","timestamp":1782773080525,"version":"3.54.5"},"reference-count":56,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Agency for Medical Research and Development","award":["JP25am0521010"],"award-info":[{"award-number":["JP25am0521010"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP25ama121008"],"award-info":[{"award-number":["JP25ama121008"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP25ama221339"],"award-info":[{"award-number":["JP25ama221339"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP25bm1123027"],"award-info":[{"award-number":["JP25bm1123027"]}]},{"name":"Japan Agency for Medical Research and Development","award":["25K10553"],"award-info":[{"award-number":["25K10553"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)","doi-asserted-by":"publisher","award":["JP25am0521010"],"award-info":[{"award-number":["JP25am0521010"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)","doi-asserted-by":"publisher","award":["JP25ama121008"],"award-info":[{"award-number":["JP25ama121008"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)","doi-asserted-by":"publisher","award":["JP25ama221339"],"award-info":[{"award-number":["JP25ama221339"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)","doi-asserted-by":"publisher","award":["JP25bm1123027"],"award-info":[{"award-number":["JP25bm1123027"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)","doi-asserted-by":"publisher","award":["25K10553"],"award-info":[{"award-number":["25K10553"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Eph receptor B2 (EphB2) overexpression is associated with poor clinical outcomes in various tumors. EphB2 is involved in malignant tumor progression through the promotion of invasiveness and metastasis. Genetic and transcriptome analyses implicated that EphB2 is a therapeutic target for specific tumor types. A monoclonal antibody (mAb) is one of the essential therapeutic strategies for EphB2-positive tumors. We previously developed an anti-EphB2 mAb, Eb2Mab-12 (IgG1, kappa), by immunizing mice with EphB2-overexpressed glioblastoma. Eb2Mab-12 specifically reacted with the EphB2-overexpressed Chinese hamster ovary-K1 (CHO\/EphB2) and some cancer cell lines in flow cytometry. In this study, we engineered Eb2Mab-12 into a mouse IgG2a type (Eb2Mab-12-mG2a) and a human IgG1-type (Eb2Mab-12-hG1) mAb. Eb2Mab-12-mG2a and Eb2Mab-12-hG1 retained the reactivity to EphB2-positive cells and exerted antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in the presence of effector cells and complements, respectively. In CHO\/EphB2, triple-negative breast cancer, and lung mesothelioma xenograft models, both Eb2Mab-12-mG2a and Eb2Mab-12-hG1 exhibited potent antitumor efficacy. These results indicated that Eb2Mab-12-derived mAbs could be applied to mAb-based therapy against EphB2-positive tumors.<\/jats:p>","DOI":"10.3390\/ijms26178302","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:31:12Z","timestamp":1756373472000},"page":"8302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["EphB2-Targeting Monoclonal Antibodies Exerted Antitumor Activities in Triple-Negative Breast Cancer and Lung Mesothelioma Xenograft Models"],"prefix":"10.3390","volume":"26","author":[{"given":"Rena","family":"Ubukata","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-4474","authenticated-orcid":false,"given":"Tomokazu","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"110556","DOI":"10.1016\/j.isci.2024.110556","article-title":"Recent advances of the Ephrin and Eph family in cardiovascular development and pathologies","volume":"27","author":"Zhu","year":"2024","journal-title":"iScience"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.tibs.2024.10.002","article-title":"Eph receptor signaling complexes in the plasma membrane","volume":"49","author":"Pasquale","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Anderton, M., van der Meulen, E., Blumenthal, M.J., and Sch\u00e4fer, G. (2021). The Role of the Eph Receptor Family in Tumorigenesis. Cancers, 13.","DOI":"10.3390\/cancers13020206"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1038\/s41388-019-0931-2","article-title":"Eph receptor signalling: From catalytic to non-catalytic functions","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: Bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrm1662","article-title":"Eph receptor signalling casts a wide net on cell behaviour","volume":"6","author":"Pasquale","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Arora, S., Scott, A.M., and Janes, P.W. (2023). Eph Receptors in Cancer. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020315"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110579","DOI":"10.1016\/j.cellsig.2022.110579","article-title":"Signals transduced by Eph receptors and ephrin ligands converge on MAP kinase and AKT pathways in human cancers","volume":"104","author":"Lau","year":"2023","journal-title":"Cell Signal"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liu, W., Yu, C., Li, J., and Fang, J. (2022). The Roles of EphB2 in Cancer. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.788587"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10549-014-3147-8","article-title":"Wild-type p53 inhibits pro-invasive properties of TGF-\u03b23 in breast cancer, in part through regulation of EPHB2, a new TGF-\u03b2 target gene","volume":"148","author":"Lam","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.omtn.2021.05.002","article-title":"circMELK promotes glioblastoma multiforme cell tumorigenesis through the miR-593\/EphB2 axis","volume":"25","author":"Zhou","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/JTO.0b013e31829ceb6a","article-title":"Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior","volume":"8","author":"Goparaju","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/0008-5472.CAN-21-0184","article-title":"EPHB2 Activates \u03b2-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma","volume":"81","author":"Leung","year":"2021","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/0008-5472.CAN-03-3667","article-title":"The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells","volume":"64","author":"Nakada","year":"2004","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0002-9440(10)62998-7","article-title":"EphB2\/R-Ras signaling regulates glioma cell adhesion, growth, and invasion","volume":"167","author":"Nakada","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Toracchio, L., Carrabotta, M., Mancarella, C., Morrione, A., and Scotlandi, K. (2024). EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212191"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cha, J.H., Chan, L.C., Wang, Y.N., Chu, Y.Y., Wang, C.H., Lee, H.H., Xia, W., Shyu, W.C., Liu, S.P., and Yao, J. (2022). Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.101817"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.acr.2020.04.007","article-title":"Eph receptors as cancer targets for antibody-based therapy","volume":"147","author":"Tang","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1007\/s11033-020-05571-8","article-title":"Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics","volume":"47","author":"London","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13543784.2020.1762566","article-title":"The role of Eph receptors in cancer and how to target them: Novel approaches in cancer treatment","volume":"29","author":"Buckens","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.biocel.2018.10.006","article-title":"Therapeutic potential of targeting the Eph\/ephrin signaling complex","volume":"105","author":"Saha","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Taki, S., Kamada, H., Inoue, M., Nagano, K., Mukai, Y., Higashisaka, K., Yoshioka, Y., Tsutsumi, Y., and Tsunoda, S. (2015). A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144712"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/0008-5472.CAN-03-1047","article-title":"EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer","volume":"64","author":"Mao","year":"2004","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Janes, P.W., Vail, M.E., Gan, H.K., and Scott, A.M. (2020). Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals, 13.","DOI":"10.3390\/ph13050088"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lehmann, B.D., Jovanovi\u0107, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., Sanders, M.E., and Pietenpol, J.A. (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157368"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000455820","article-title":"Biological Subtypes of Triple-Negative Breast Cancer","volume":"12","author":"Hubalek","year":"2017","journal-title":"Breast Care"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Limsakul, P., Choochuen, P., Jungrungrueang, T., and Charupanit, K. (2024). Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031405"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41582-022-00679-w","article-title":"Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours","volume":"18","author":"Horbinski","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nature09173","article-title":"Cross-species genomics matches driver mutations and cell compartments to model ependymoma","volume":"466","author":"Johnson","year":"2010","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/2159-8290.CD-20-1066","article-title":"ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma","volume":"11","author":"Arabzade","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Satofuka, H., Suzuki, H., Tanaka, T., Li, G., Kaneko, M.K., and Kato, Y. (2025). Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications. Biochem. Biophys. Rep., 42.","DOI":"10.1016\/j.bbrep.2025.101998"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Satofuka, H., Suzuki, H., Hirose, M., Shinoda, K., Nakamura, T., Tanaka, T., Kaneko, M.K., and Kato, Y. (2025). Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry. Biochem. Biophys. Rep., 43.","DOI":"10.1016\/j.bbrep.2025.102130"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ubukata, R., Suzuki, H., Hirose, M., Satofuka, H., Tanaka, T., Kaneko, M.K., and Kato, Y. (2025). Establishment of a highly sensitive and specific anti-EphB2 monoclonal antibody (Eb2Mab-12) for flow cytometry. Microbes Immun.","DOI":"10.20944\/preprints202406.0704.v2"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/mab.2023.0015","article-title":"Development of an Anti-EphB4 Monoclonal Antibody for Multiple Applications Against Breast Cancers","volume":"42","author":"Nanamiya","year":"2023","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tanaka, T., Kaneko, Y., Yamamoto, H., Li, G., Fujisawa, S., Satofuka, H., Shinoda, K., Nakamura, T., Kaneko, M.K., and Suzuki, H. (2025). Development of a novel anti-erythropoietin-producing hepatocellular receptor B6 monoclonal antibody Eb6Mab-3 for flow cytometry. Biochem. Biophys. Rep., 41.","DOI":"10.1016\/j.bbrep.2025.101960"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kaneko, M.K., Suzuki, H., Ohishi, T., Nakamura, T., Tanaka, T., and Kato, Y. (2024). A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031941"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kaneko, M.K., Suzuki, H., Ohishi, T., Nakamura, T., Yanaka, M., Tanaka, T., and Kato, Y. (2025). Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH(2)Mab-250 in Human Breast Cancer Xenografts. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031079"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"Overdijk","year":"2012","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","article-title":"Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers","volume":"18","author":"Pegram","year":"1999","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/sj.onc.1202132","article-title":"Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs","volume":"17","author":"Pietras","year":"1998","journal-title":"Oncogene"},{"key":"ref_47","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","article-title":"Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors","volume":"17","author":"Montero","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tong, Y., Fan, X., Liu, H., and Liang, T. (2024). Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1495675"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Izci, H., Punie, K., Waumans, L., Laenen, A., Wildiers, H., Verdoodt, F., Desmedt, C., Ardui, J., Smeets, A., and Han, S.N. (2022). Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-27093-y"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/cas.70103","article-title":"Antitumor Activities by a Humanized Cancer-Specific Anti-Podoplanin Monoclonal Antibody humPMab-117 Against Human Tumors","volume":"116","author":"Tanaka","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-05-1855","article-title":"Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model","volume":"12","author":"Reusch","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: The complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1470-2045(08)70342-5","article-title":"Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study","volume":"10","author":"Merchant","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2319474122","DOI":"10.1073\/pnas.2319474122","article-title":"Targeting EPHB2\/ABL1 restores antitumor immunity in preclinical models of ependymoma","volume":"122","author":"Ren","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijmm.2023.5221","article-title":"Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models","volume":"51","author":"Li","year":"2023","journal-title":"Int. J. Mol. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8302\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:39Z","timestamp":1760034819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":56,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178302"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178302","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}